Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2015-02-18

FDA Approved: ISENTRESS — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

This FDA entry announces a supplemental application for ISENTRESS (raltegravir) filed by Merck Sharp & Dohme LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Isentress (Raltegravir)

Snippet

SUPPL AP for ISENTRESS (RALTEGRAVIR)